Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 83

1.

Race, financial hardship, and limiting care due to cost in a diverse cohort of cancer survivors.

Hastert TA, Banegas MP, Hamel LM, Reed AR, Baird T, Beebe-Dimmer JL, Schwartz AG.

J Cancer Surviv. 2019 Jun;13(3):429-437. doi: 10.1007/s11764-019-00764-y. Epub 2019 May 29.

PMID:
31144264
2.

Racial differences in patterns of treatment among men diagnosed with de novo advanced prostate cancer: A SEER-Medicare investigation.

Beebe-Dimmer JL, Ruterbusch JJ, Cooney KA, Bolton A, Schwartz K, Schwartz AG, Heath E.

Cancer Med. 2019 Jun;8(6):3325-3335. doi: 10.1002/cam4.2092. Epub 2019 May 15.

3.

Mitochondrial alterations may underlie race-specific differences in cancer risk and outcome.

Beebe-Dimmer JL, Cooney KA.

J Clin Invest. 2019 May 6;129(6):2187-2188. doi: 10.1172/JCI128707. eCollection 2019 May 6.

4.

Financial Hardship and Quality of Life among African American and White Cancer Survivors: The Role of Limiting Care Due to Cost.

Hastert TA, Kyko JM, Reed AR, Harper FWK, Beebe-Dimmer JL, Baird TE, Schwartz AG.

Cancer Epidemiol Biomarkers Prev. 2019 Jul;28(7):1202-1211. doi: 10.1158/1055-9965.EPI-18-1336. Epub 2019 May 6.

PMID:
31061097
5.

The Epidemiology of Cancer Among Homeless Adults in Metropolitan Detroit.

Holowatyj AN, Heath EI, Pappas LM, Ruterbusch JJ, Gorski DH, Triest JA, Park HK, Beebe-Dimmer JL, Schwartz AG, Cote ML, Schwartz KL.

JNCI Cancer Spectr. 2019 Mar;3(1):pkz006. doi: 10.1093/jncics/pkz006. Epub 2019 Mar 25.

6.

Metabolic syndrome and risk of endometrial cancer in postmenopausal women: a prospective study.

Arthur RS, Kabat GC, Kim MY, Wild RA, Shadyab AH, Wactawski-Wende J, Ho GYF, Reeves KW, Kuller LH, Luo J, Beebe-Dimmer J, Simon MS, Strickler H, Wassertheil-Smoller S, Rohan TE.

Cancer Causes Control. 2019 Apr;30(4):355-363. doi: 10.1007/s10552-019-01139-5. Epub 2019 Feb 20.

PMID:
30788634
7.

First-year weight loss with androgen-deprivation therapy increases risks of prostate cancer progression and prostate cancer-specific mortality: results from SEARCH.

Griffin K, Csizmadi I, Howard LE, Pomann GM, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Terris MK, Beebe-Dimmer J, Freedland SJ.

Cancer Causes Control. 2019 Mar;30(3):259-269. doi: 10.1007/s10552-019-1133-5. Epub 2019 Jan 30.

PMID:
30701374
8.

Biliary tract cancer incidence and trends in the United States by demographic group, 1999-2013.

Van Dyke AL, Shiels MS, Jones GS, Pfeiffer RM, Petrick JL, Beebe-Dimmer JL, Koshiol J.

Cancer. 2019 May 1;125(9):1489-1498. doi: 10.1002/cncr.31942. Epub 2019 Jan 15.

PMID:
30645774
9.

The Detroit Research on Cancer Survivors (ROCS) Pilot Study: A Focus on Outcomes after Cancer in a Racially Diverse Patient Population.

Beebe-Dimmer JL, Albrecht TL, Baird TE, Ruterbusch JJ, Hastert T, Harper FWK, Simon MS, Abrams J, Schwartz KL, Schwartz AG.

Cancer Epidemiol Biomarkers Prev. 2019 Apr;28(4):666-674. doi: 10.1158/1055-9965.EPI-18-0123. Epub 2018 Nov 27.

PMID:
30482875
10.

The extrema of circulating miR-17 are identified as biomarkers for aggressive prostate cancer.

Dyson G, Farran B, Bolton S, Craig DB, Dombkowski A, Beebe-Dimmer JL, Powell IJ, Podgorski I, Heilbrun LK, Bock CH.

Am J Cancer Res. 2018 Oct 1;8(10):2088-2095. eCollection 2018.

11.

Risk of incident claims for chemotherapy-induced peripheral neuropathy among women with breast cancer in a Medicare population.

Greenwald MK, Ruterbusch JJ, Beebe-Dimmer JL, Simon MS, Albrecht TL, Schwartz AG.

Cancer. 2019 Jan 15;125(2):269-277. doi: 10.1002/cncr.31798. Epub 2018 Nov 2.

PMID:
30387871
12.

Real-world testing and treatment patterns in chronic lymphocytic leukemia: A SEER patterns of care analysis.

Seymour EK, Ruterbusch JJ, Beebe-Dimmer JL, Schiffer CA.

Cancer. 2019 Jan 1;125(1):135-143. doi: 10.1002/cncr.31738. Epub 2018 Oct 21.

PMID:
30343488
13.

Correction to: Patterns of Bicalutamide Use in Prostate Cancer Treatment: A U.S. Real-World Analysis Using the SEER-Medicare Database.

Beebe-Dimmer JL, Ruterbusch JJ, Bylsma LC, Gillezeau C, Fryzek J, Schultz NM, Flanders SC, Barlev A, Heath E, Quek RGW.

Adv Ther. 2018 Sep;35(9):1452. doi: 10.1007/s12325-018-0767-0.

14.

Finding a Needle in the Haystack: The Search for Germline Variants Associated with Prostate Cancer Clinical Outcomes.

Cooney KA, Beebe-Dimmer JL.

Eur Urol. 2018 Dec;74(6):720-721. doi: 10.1016/j.eururo.2018.07.001. Epub 2018 Jul 17. No abstract available.

PMID:
30029823
15.

Patterns of Bicalutamide Use in Prostate Cancer Treatment: A U.S. Real-World Analysis Using the SEER-Medicare Database.

Beebe-Dimmer JL, Ruterbusch JJ, Bylsma LC, Gillezeau C, Fryzek J, Schultz NM, Flanders SC, Barlev A, Heath E, Quek RGW.

Adv Ther. 2018 Sep;35(9):1438-1451. doi: 10.1007/s12325-018-0738-5. Epub 2018 Jun 26. Erratum in: Adv Ther. 2018 Aug 16;:.

16.

Development of a reliable assay to measure glypican-1 in plasma and serum reveals circulating glypican-1 as a novel prostate cancer biomarker.

Levin RA, Lund ME, Truong Q, Wu A, Shore ND, Saltzstein DR, Concepcion RS, Paivanas TA, van Breda A, Beebe-Dimmer J, Ruterbusch JJ, Wissmueller S, Campbell DH, Walsh BJ.

Oncotarget. 2018 Apr 27;9(32):22359-22367. doi: 10.18632/oncotarget.25009. eCollection 2018 Apr 27.

17.

Detection of glypican-1 (GPC-1) expression in urine cell sediments in prostate cancer.

Campbell DH, Lund ME, Nocon AL, Cozzi PJ, Frydenberg M, De Souza P, Schiller B, Beebe-Dimmer JL, Ruterbusch JJ, Walsh BJ.

PLoS One. 2018 Apr 19;13(4):e0196017. doi: 10.1371/journal.pone.0196017. eCollection 2018.

18.

Comparing Treatment Strategies for Stage I Small-cell lung Cancer.

Paximadis P, Beebe-Dimmer JL, George J, Schwartz AG, Wozniak A, Gadgeel S.

Clin Lung Cancer. 2018 Sep;19(5):e559-e565. doi: 10.1016/j.cllc.2018.03.017. Epub 2018 Mar 23.

19.

Clinical and economic burden associated with stage III to IV triple-negative breast cancer: A SEER-Medicare historical cohort study in elderly women in the United States.

Schwartz KL, Simon MS, Bylsma LC, Ruterbusch JJ, Beebe-Dimmer JL, Schultz NM, Flanders SC, Barlev A, Fryzek JP, Quek RGW.

Cancer. 2018 May 15;124(10):2104-2114. doi: 10.1002/cncr.31299. Epub 2018 Mar 5.

20.

A study of circulating microRNAs identifies a new potential biomarker panel to distinguish aggressive prostate cancer.

Farran B, Dyson G, Craig D, Dombkowski A, Beebe-Dimmer JL, Powell IJ, Podgorski I, Heilbrun L, Bolton S, Bock CH.

Carcinogenesis. 2018 Apr 5;39(4):556-561. doi: 10.1093/carcin/bgy025.

PMID:
29471417
21.

Rare germline mutations in African American men diagnosed with early-onset prostate cancer.

Beebe-Dimmer JL, Zuhlke KA, Johnson AM, Liesman D, Cooney KA.

Prostate. 2018 Apr;78(5):321-326. doi: 10.1002/pros.23464. Epub 2018 Jan 21.

22.

Cardiometabolic risk factors and survival after breast cancer in the Women's Health Initiative.

Simon MS, Beebe-Dimmer JL, Hastert TA, Manson JE, Cespedes Feliciano EM, Neuhouser ML, Ho GYF, Freudenheim JL, Strickler H, Ruterbusch J, Barac A, Chlebowski R, Caan B.

Cancer. 2018 Apr 15;124(8):1798-1807. doi: 10.1002/cncr.31230. Epub 2018 Jan 16.

23.

Family history of prostate and colorectal cancer and risk of colorectal cancer in the Women's health initiative.

Beebe-Dimmer JL, Yee C, Paskett E, Schwartz AG, Lane D, Palmer NRA, Bock CH, Nassir R, Simon MS.

BMC Cancer. 2017 Dec 13;17(1):848. doi: 10.1186/s12885-017-3873-5.

24.

The effect of genetic variants on the relationship between statins and breast cancer in postmenopausal women in the Women's Health Initiative observational study.

Bock CH, Jay AM, Dyson G, Beebe-Dimmer JL, Cote ML, Hou L, Howard BV, Desai P, Purrington K, Prentice R, Simon MS.

Breast Cancer Res Treat. 2018 Feb;167(3):741-749. doi: 10.1007/s10549-017-4521-0. Epub 2017 Oct 24.

25.

Risk of Second Lung Cancer in Patients with Previously Treated Lung Cancer: Analysis of Surveillance, Epidemiology, and End Results (SEER) Data.

Thakur MK, Ruterbusch JJ, Schwartz AG, Gadgeel SM, Beebe-Dimmer JL, Wozniak AJ.

J Thorac Oncol. 2018 Jan;13(1):46-53. doi: 10.1016/j.jtho.2017.09.1964. Epub 2017 Oct 5.

26.

Metabolic Obesity Phenotypes and Risk of Breast Cancer in Postmenopausal Women.

Kabat GC, Kim MY, Lee JS, Ho GY, Going SB, Beebe-Dimmer J, Manson JE, Chlebowski RT, Rohan TE.

Cancer Epidemiol Biomarkers Prev. 2017 Dec;26(12):1730-1735. doi: 10.1158/1055-9965.EPI-17-0495. Epub 2017 Sep 22.

27.

Interaction between Nonsteroidal Anti-inflammatory Drugs and Low-fat Dietary Intervention on Colorectal Cancer Incidence; the Women's Health Initiative (WHI) Dietary Modification Trial.

Kato I, Lane D, Womack CR, Bock CH, Hou L, Lin JH, Wu C, Beebe Dimmer J, Simon MS.

J Am Coll Nutr. 2017 Aug;36(6):462-469. doi: 10.1080/07315724.2017.1321505. Epub 2017 Jul 6.

28.

Familial prostate cancer.

Giri VN, Beebe-Dimmer JL.

Semin Oncol. 2016 Oct;43(5):560-565. doi: 10.1053/j.seminoncol.2016.08.001. Epub 2016 Aug 18.

PMID:
27899188
29.

Mesothelioma in the United States: a Surveillance, Epidemiology, and End Results (SEER)-Medicare investigation of treatment patterns and overall survival.

Beebe-Dimmer JL, Fryzek JP, Yee CL, Dalvi TB, Garabrant DH, Schwartz AG, Gadgeel S.

Clin Epidemiol. 2016 Oct 26;8:743-750. eCollection 2016.

30.

Editorial Comment.

Beebe-Dimmer J, Cooney KA.

J Urol. 2017 Jan;197(1):66. doi: 10.1016/j.juro.2016.06.106. Epub 2016 Oct 4. No abstract available.

PMID:
27717687
31.

HOXB13 mutations and prostate cancer risk.

Cooney KA, Beebe-Dimmer JL.

BJU Int. 2016 Oct;118(4):496-7. doi: 10.1111/bju.13477. No abstract available.

32.

The HOXB13 G84E Mutation Is Associated with an Increased Risk for Prostate Cancer and Other Malignancies.

Beebe-Dimmer JL, Hathcock M, Yee C, Okoth LA, Ewing CM, Isaacs WB, Cooney KA, Thibodeau SN.

Cancer Epidemiol Biomarkers Prev. 2015 Sep;24(9):1366-72. doi: 10.1158/1055-9965.EPI-15-0247. Epub 2015 Jun 24.

33.

Familial clustering of breast and prostate cancer and risk of postmenopausal breast cancer in the Women's Health Initiative Study.

Beebe-Dimmer JL, Yee C, Cote ML, Petrucelli N, Palmer N, Bock C, Lane D, Agalliu I, Stefanick ML, Simon MS.

Cancer. 2015 Apr 15;121(8):1265-72. doi: 10.1002/cncr.29075. Epub 2015 Mar 9.

34.

Statins and breast cancer stage and mortality in the Women's Health Initiative.

Desai P, Lehman A, Chlebowski RT, Kwan ML, Arun M, Manson JE, Lavasani S, Wasswertheil-Smoller S, Sarto GE, LeBoff M, Cauley J, Cote M, Beebe-Dimmer J, Jay A, Simon MS.

Cancer Causes Control. 2015 Apr;26(4):529-39. doi: 10.1007/s10552-015-0530-7. Epub 2015 Mar 4.

35.

The cancer burden attributable to biologic agents.

Schottenfeld D, Beebe-Dimmer J.

Ann Epidemiol. 2015 Mar;25(3):183-7. doi: 10.1016/j.annepidem.2014.11.016. Epub 2014 Nov 20. Review.

PMID:
25523895
36.

Antioxidant micronutrients and the risk of renal cell carcinoma in the Women's Health Initiative cohort.

Ho WJ, Simon MS, Yildiz VO, Shikany JM, Kato I, Beebe-Dimmer JL, Cetnar JP, Bock CH.

Cancer. 2015 Feb 15;121(4):580-8. doi: 10.1002/cncr.29091. Epub 2014 Oct 9.

37.

Association of cancer susceptibility variants with risk of multiple primary cancers: The population architecture using genomics and epidemiology study.

Park SL, Caberto CP, Lin Y, Goodloe RJ, Dumitrescu L, Love SA, Matise TC, Hindorff LA, Fowke JH, Schumacher FR, Beebe-Dimmer J, Chen C, Hou L, Thomas F, Deelman E, Han Y, Peters U, North KE, Heiss G, Crawford DC, Haiman CA, Wilkens LR, Bush WS, Kooperberg C, Cheng I, Le Marchand L.

Cancer Epidemiol Biomarkers Prev. 2014 Nov;23(11):2568-78. doi: 10.1158/1055-9965.EPI-14-0129. Epub 2014 Aug 19.

38.

Risk of second primary tumors in men diagnosed with prostate cancer: a population-based cohort study.

Davis EJ, Beebe-Dimmer JL, Yee CL, Cooney KA.

Cancer. 2014 Sep 1;120(17):2735-41. doi: 10.1002/cncr.28769. Epub 2014 May 19.

39.

Gene-environment interactions between JAZF1 and occupational and household lead exposure in prostate cancer among African American men.

Neslund-Dudas C, Levin AM, Beebe-Dimmer JL, Bock CH, Nock NL, Rundle A, Jankowski M, Krajenta R, Dou QP, Mitra B, Tang D, Rebbeck TR, Rybicki BA.

Cancer Causes Control. 2014 Jul;25(7):869-79. doi: 10.1007/s10552-014-0387-1. Epub 2014 May 7.

40.

Case-only gene-environment interaction between ALAD tagSNPs and occupational lead exposure in prostate cancer.

Neslund-Dudas C, Levin AM, Rundle A, Beebe-Dimmer J, Bock CH, Nock NL, Jankowski M, Datta I, Krajenta R, Dou QP, Mitra B, Tang D, Rybicki BA.

Prostate. 2014 May;74(6):637-46. doi: 10.1002/pros.22781. Epub 2014 Feb 5.

41.

Prevalence of the HOXB13 G84E prostate cancer risk allele in men treated with radical prostatectomy.

Beebe-Dimmer JL, Isaacs WB, Zuhlke KA, Yee C, Walsh PC, Isaacs SD, Johnson AM, Ewing CE, Humphreys EB, Chowdhury WH, Montie JE, Cooney KA.

BJU Int. 2014 May;113(5):830-5. doi: 10.1111/bju.12522. Epub 2014 Mar 5.

42.

Current perspective on the global and United States cancer burden attributable to lifestyle and environmental risk factors.

Schottenfeld D, Beebe-Dimmer JL, Buffler PA, Omenn GS.

Annu Rev Public Health. 2013;34:97-117. doi: 10.1146/annurev-publhealth-031912-114350. Review.

PMID:
23514316
43.

Androgen deprivation therapy: further confirmation of known harms.

Beebe-Dimmer JL, Freedland SJ.

BJU Int. 2013 May;111(5):690-1. doi: 10.1111/j.1464-410X.2013.11797.x. Epub 2013 Feb 18. No abstract available.

44.

An investigation of risk factors for renal cell carcinoma by histologic subtype in two case-control studies.

Purdue MP, Moore LE, Merino MJ, Boffetta P, Colt JS, Schwartz KL, Bencko V, Davis FG, Graubard BI, Janout V, Ruterbusch JJ, Beebe-Dimmer J, Cote ML, Shuch B, Mates D, Hofmann JN, Foretova L, Rothman N, Szeszenia-Dabrowska N, Matveev V, Wacholder S, Zaridze D, Linehan WM, Brennan P, Chow WH.

Int J Cancer. 2013 Jun 1;132(11):2640-7. doi: 10.1002/ijc.27934. Epub 2013 Jan 15.

45.

Body mass index and renal cell cancer: the influence of race and sex.

Beebe-Dimmer JL, Colt JS, Ruterbusch JJ, Keele GR, Purdue MP, Wacholder S, Graubard BI, Davis F, Chow WH, Schwartz KL.

Epidemiology. 2012 Nov;23(6):821-8. doi: 10.1097/EDE.0b013e31826b7fe9.

46.

Hypertension, obesity and prostate cancer biochemical recurrence after radical prostatectomy.

Asmar R, Beebe-Dimmer JL, Korgavkar K, Keele GR, Cooney KA.

Prostate Cancer Prostatic Dis. 2013 Mar;16(1):62-6. doi: 10.1038/pcan.2012.32. Epub 2012 Aug 21.

47.

Genetic variation in glutathione S-transferase omega-1, arsenic methyltransferase and methylene-tetrahydrofolate reductase, arsenic exposure and bladder cancer: a case-control study.

Beebe-Dimmer JL, Iyer PT, Nriagu JO, Keele GR, Mehta S, Meliker JR, Lange EM, Schwartz AG, Zuhlke KA, Schottenfeld D, Cooney KA.

Environ Health. 2012 Jun 29;11:43. doi: 10.1186/1476-069X-11-43.

48.

Timing of androgen deprivation therapy use and fracture risk among elderly men with prostate cancer in the United States.

Beebe-Dimmer JL, Cetin K, Shahinian V, Morgenstern H, Yee C, Schwartz KL, Acquavella J.

Pharmacoepidemiol Drug Saf. 2012 Jan;21(1):70-8. doi: 10.1002/pds.2258. Epub 2011 Nov 24.

49.

The Metabolic Syndrome and Biochemical Recurrence following Radical Prostatectomy.

Post JM, Beebe-Dimmer JL, Morgenstern H, Neslund-Dudas C, Bock CH, Nock N, Rundle A, Jankowski M, Rybicki BA.

Prostate Cancer. 2011;2011:245642. doi: 10.1155/2011/245642. Epub 2011 Sep 25.

50.

Red wine consumption is inversely associated with 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine-DNA adduct levels in prostate.

Rybicki BA, Neslund-Dudas C, Bock CH, Nock NL, Rundle A, Jankowski M, Levin AM, Beebe-Dimmer J, Savera AT, Takahashi S, Shirai T, Tang D.

Cancer Prev Res (Phila). 2011 Oct;4(10):1636-44. doi: 10.1158/1940-6207.CAPR-11-0100. Epub 2011 Aug 16.

Supplemental Content

Loading ...
Support Center